Is Coherus BioSciences Stock a Good Investment?
Coherus BioSciences Investment Advice | CHRS |
- Examine Coherus BioSciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Coherus BioSciences' leadership team and their track record. Good management can help Coherus BioSciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Coherus BioSciences' business and its evolving consumer preferences.
- Compare Coherus BioSciences' performance and market position to its competitors. Analyze how Coherus BioSciences is positioned in terms of product offerings, innovation, and market share.
- Check if Coherus BioSciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Coherus BioSciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Coherus BioSciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Coherus BioSciences is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Coherus BioSciences Stock
Researching Coherus BioSciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 58.0% of the company shares are held by institutions such as insurance companies. The company last dividend was issued on the June 26, 1995. Coherus BioSciences had 2:1 split on the December 8, 1992.
To determine if Coherus BioSciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Coherus BioSciences' research are outlined below:
| Coherus BioSciences generated a negative expected return over the last 90 days | |
| Coherus BioSciences has high historical volatility and very poor performance | |
| Coherus BioSciences has some characteristics of a very speculative penny stock | |
| Coherus BioSciences has high likelihood to experience some financial distress in the next 2 years | |
| Coherus BioSciences currently holds about 275.48 M in cash with (20.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.54, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 58.0% of the company shares are held by institutions such as insurance companies |
Coherus BioSciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Coherus BioSciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Coherus BioSciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Coherus BioSciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 119.37 M.Coherus BioSciences' profitablity analysis
The company has Profit Margin (PM) of 0.11 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (0.66) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.66.Determining Coherus BioSciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Coherus BioSciences is a good buy. For example, gross profit margin measures Coherus BioSciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Coherus BioSciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Coherus BioSciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Coherus BioSciences. Check Coherus BioSciences' Beneish M Score to see the likelihood of Coherus BioSciences' management manipulating its earnings.
Basic technical analysis of Coherus Stock
As of the 24th of March, Coherus BioSciences shows the Standard Deviation of 5.27, risk adjusted performance of (0.09), and Mean Deviation of 3.92. Coherus BioSciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Coherus BioSciences mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and kurtosis to decide if Coherus BioSciences is priced correctly, providing market reflects its regular price of 0.95 per share. Given that Coherus BioSciences is a hitting penny stock territory we recommend to closely look at its jensen alpha.Coherus BioSciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Coherus BioSciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Coherus BioSciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Coherus BioSciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Coherus BioSciences' Outstanding Corporate Bonds
Coherus BioSciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Coherus BioSciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Coherus bonds can be classified according to their maturity, which is the date when Coherus BioSciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| CCOI 7 15 JUN 27 Corp BondUS19240CAE30 | View | |
| US19240CAC73 Corp BondUS19240CAC73 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Coherus BioSciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Coherus BioSciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | 0.6233 | |||
| Mean Deviation | 3.92 | |||
| Coefficient Of Variation | (911.66) | |||
| Standard Deviation | 5.27 | |||
| Variance | 27.81 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (0.38) | |||
| Treynor Ratio | 0.6133 | |||
| Maximum Drawdown | 31.16 | |||
| Value At Risk | (8.00) | |||
| Potential Upside | 8.42 | |||
| Skewness | 0.7742 | |||
| Kurtosis | 2.17 |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | 0.6233 | |||
| Mean Deviation | 3.92 | |||
| Coefficient Of Variation | (911.66) | |||
| Standard Deviation | 5.27 | |||
| Variance | 27.81 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (0.38) | |||
| Treynor Ratio | 0.6133 | |||
| Maximum Drawdown | 31.16 | |||
| Value At Risk | (8.00) | |||
| Potential Upside | 8.42 | |||
| Skewness | 0.7742 | |||
| Kurtosis | 2.17 |
Consider Coherus BioSciences' intraday indicators
Coherus BioSciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Coherus BioSciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 260312.0 | |||
| Daily Balance Of Power | (0.67) | |||
| Rate Of Daily Change | 0.92 | |||
| Day Median Price | 1.01 | |||
| Day Typical Price | 0.99 | |||
| Price Action Indicator | (0.10) | |||
| Period Momentum Indicator | (0.08) |
Coherus Stock media impact
Far too much social signal, news, headlines, and media speculation about Coherus BioSciences that are available to investors today. That information is available publicly through Coherus media outlets and privately through word of mouth or via Coherus internal channels. However, regardless of the origin, that massive amount of Coherus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Coherus BioSciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Coherus BioSciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Coherus BioSciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Coherus BioSciences alpha.
Coherus BioSciences Corporate Management
| Vladimir Vexler | Chief Scientific Officer | Profile | |
| Bryan Mcmichael | Principal Accounting | Profile | |
| Michael Chen | Senior Trade | Profile | |
| Theresa Lavallee | Chief Board | Profile | |
| MRCP MD | Chief Officer | Profile | |
| Rebecca Sunshine | Chief Officer | Profile |
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.